Tag Archives: Bloomberg Intelligence

Teva stock crashes on 2Q earnings disaster; run for the hills, or buy at fire sale price?

The News: Teva Pharmaceutical Industries Ltd., which has been without a permanent CEO for six months, plunged $11.74, or 36% last week, to $20.60–the most in almost two decades. The… Read more »

GOP Senate bill ignites massive rally in healthcare stocks; remember the dot-com era?

US healthcare stocks posted sharp gains last week, with pharma, hospitals and insurers climbing after Senate Republicans released a draft bill to scrap Obamacare, while a recent explosion in biotech… Read more »

NIH proves immune to Trump’s budget scalpel

The News: Lawmakers expanded instead of slashed the budget for the National Institutes of Health (NIH) in its bipartisan deal to fund the government earlier this week, essentially snubbing the… Read more »

Anthem defies Wall Street, rivals, with stellar 1Q results pegged to Obamacare business

The News: Anthem Inc. (Indianapolis IN), which has 1.1 million customers in individual Obamacare plans, said it was moving ahead with its 2018 insurance filings but had told state regulators… Read more »

Icahn’s latest target, Bristol-Myers, may play hard-to-get; unless Pfizer comes a courting

The News: Activist investor Carl Icahn just announced his latest target: Bristol-Myers Squibb Co., reports the Wall Street Journal. Bristol-Myers has been the focus of several activist investors in recent… Read more »

Teva’s CEO Vigodman history; sudden departure calls for fearless successor

The News: Teva Pharmaceutical Industries Ltd. (Petach Tikva ISR) suddenly found itself without a permanent CEO on Tuesday (February 7, 2017) after Erez Vigodman stepped down, leaving new management to… Read more »

Pfizer stumbles to 4Q profit after rough year for Prevnar; what happened to industry leadership role?

News: Pfizer Inc.’s (New York City) key pneumococcal vaccine, Prevnar, whose sales soared through 2015, stumbled in fourth-quarter results (pdf) released last week. The blockbuster inoculation fell significantly short of Street… Read more »

J&J finally captures Actelion for $30 billion; deal looks good for both unless “what ifs” bite pharma giant’s shareholders

The News: It took months but Swiss biotech Actelion Ltd. (Allschwil) said on Thursday (January 26, 2017) it had agreed to be purchased by Johnson & Johnson (New Brunswick NJ) in a… Read more »

Good News for Mylan after Hellish Week: Another Win in Patent War Over MS Drug; Lawyers on Both Sides Rejoice.

Teva Pharmaceutical Industries Ltd. (Petach Tikva ISR) had a third patent on its top-selling multiple sclerosis drug, Copaxone, invalidated last Thursday by a U.S. agency, a further blow to its… Read more »